- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02834078
Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome (Glucogold)
Effect of 'Berberine Glucogold' [BGG] on Glucose Metabolism in Individuals With Marginally Impaired Glucose Metabolism Along With Other Markers of Metabolic Syndrome
According to the International Diabetes Federation, one in every 12 individuals is a diabetic (about 8% of the world population). Major risk factors of diabetes are all the aspects of modern life which include obesity, over-weight, high-risk behavior like smoking, alcohol, multiple drug use-recreational or prescribed, environmental risk factors like inactivity and lack of exercise. However there is a window of opportunity between health and disease, which is pre-diabetes.
Pre-diabetes has been defined by American Diabetes Association as Impaired Glucose Tolerance (IGT) which is 7.8 -11.0 mmol/l, Impaired Fasting Glucose Test (IFT) which is 5.6-6.9mmol/l and now added Glycosylated Hemoglobin (HbA1c) of 5.7% to 6.4%.
Though there are plenty of drugs available for significantly impaired glucose metabolism (including oral hypoglycemic agents and insulin), their use in marginally impaired glucose metabolism is questionable due to risk of untoward hypoglycemia.
On the other hand, herbal products like curcumin, as a single ingredient has poor bioavailability problem that restricts its use as standalone treatment. Inulin works as pre-biotic and help to maintain gut microbiota which is considered as precursor for progress of prediabetes to diabetes. However, it does not have any role in primary pathophysiology of impaired glucose metabolism, i.e. pancreatic β cell dysfunction, insulin resistance, hepatic gluconeogenesis or intestinal glucose absorption. Resveratrol and omega-3 basically work on anti-oxidant pathways.
None of these popular ingredients has been studied for their role in structural and functional health of pancreatic β cells which is very important for prediction of further progress of marginally impaired glucose metabolism to significantly impaired glucose metabolism.
It is an unmet need to develop a product which not only improves insulin sensitivity, but also help to preserve the structural and functional health of pancreatic β cells. It also needs to improve overall metabolic and endothelial health of the person considering the close association between impaired glucose metabolism and these parameters.
The proposed supplement - "Berberine GlucoGold "- is an improved version of successfully marketed supplement - Berberine GlucoDefense. It has a balanced composition in which all the ingredients complement each other in such a way that along with the individual role in glucose metabolism it also takes care of overall bioavailability and stability of the supplement. As per the previous data on ingredients, the supplement is also expected to preserve the structural and functional health of pancreatic β cells. The ingredients are also known to have positive effect on overall metabolic and endothelial health. Thus BGG has been developed to address the unmet needs in the area of glucose metabolism and overall metabolic health.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able and willing to provide informed consent.
- Treatment naïve male-female aged 20-60 years of age.
- BMI ≥ 25 kg/m²
- Oral glucose tolerance test (OGTT) ≥140 and ≤250 mg/dl (pre-diabetes and early diagnosed diabetes within 45 days of diagnosis)
- Patient with chronic stable illness can be included ONLY IF he/she is currently NOT on any of the medications included in prohibited list of medicines.
- Currently on herbal supplements can be included after a wash-out period of 7 days.
- Subjects willing to abstain from nicotine and alcohol in the duration of the study.
Exclusion Criteria:
- Subjects with OGTT<140 mg/dl or ≥ 250 mg/dl
- Current treatment with diabetes medications, including metformin
- Current treatment with glucocorticoids
- History of clinically significant hematological, hepatic or renal diseases, as per investigator discretion
- Uncontrolled chronic disease
- Hormonal Disorders
- Subjects on Steroids
- Subjects on Statins
- Chronic inflammatory diseases requiring any medication
- Migraine, Sinusitis
- Subjects Consuming NSAIDS for long term
- Medications include the drugs of prohibited range.
- Pregnant and lactating females.
- Subjects addicted to nicotine, alcohol or any other recreational drug.
- Subjects who are planning to fast for more than 4 days/ per month during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BGG
Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
|
|
Placebo Comparator: Placebo
Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors.
Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Oral Disposition Index
Time Frame: Day 0, Day 28, Day 56 and Day 84
|
Day 0, Day 28, Day 56 and Day 84
|
Change in Glycated hemoglobin
Time Frame: Day 0, Day 28, Day 56 and Day 84
|
Day 0, Day 28, Day 56 and Day 84
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Fasting blood sugar
Time Frame: Day 0, Day 28, Day 56 and Day 84
|
Day 0, Day 28, Day 56 and Day 84
|
Change in Body Mass Index
Time Frame: Day 0, Day 28, Day 56 and Day 84
|
Day 0, Day 28, Day 56 and Day 84
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sandip Patil, M.D., Maharashtra Council of Indian Medicine
- Principal Investigator: Rajesh Kewalramani, M.B.B.S., Maharashtra Council of Indian Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HD/150301/BGG/PD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre Diabetes
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingPre DiabetesUnited States
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPre DiabetesUnited States
-
University of ReadingBarnham Benevolent Foundation; Jason and Daphne Mermikides Charitable TrustUnknownPre DiabetesUnited Kingdom
-
University of RochesterCompleted
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
ViomeActive, not recruitingDiabetes | Pre DiabetesUnited States
-
Griffin HospitalFos BiomedicalCompleted
-
Mayo ClinicCompletedPre DiabetesUnited States
-
Wake Forest University Health SciencesCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States